;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ABT-199: Additional Phase I data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: ABT-199, RG7601 (formerly GDC-0199) Business: Cancer Molecular target: B cell lymphoma 2 (BCL-2) (BCL2) Description: Small…

    Published on 7/21/2014
  • Aclidinium bromide/formoterol fumarate: Additional Phase III data

    Almirall S.A. (Madrid:ALM), Barcelona, Spain Actavis plc (NYSE:ACT), Dublin, Ireland Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Product: Aclidinium bromide/formoterol fumarate (KRP-AB1102F, LAS40464) …

    Published on 7/21/2014
  • ALM AADx: Clinical trial data

    Almac Group Ltd., Craigavon, U.K. Product: ALM AADx Business: Diagnostic Molecular target: NA Description: 63-gene expression signature assay Indication: Identify a subgroup of patients with high-grade serous ovarian …

    Published on 7/21/2014
  • AMG 416: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: AMG 416, ONO-5163 (formerly Velcalcetide, KAI-4169) Business: Endocrine/Metabolic Molecular target: Calcium…

    Published on 7/21/2014
  • AMT-021: Interim Phase I data

    uniQure N.V. (NASDAQ:QURE), Amsterdam, the Netherlands Product: AMT-021 Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant adeno-associated viral (AAV) vector containing the porphobilinogen …

    Published on 7/21/2014
  • BeneFIX: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: BeneFIX Business: Hematology Molecular target: Factor IX Description: Recombinant coagulation Factor IX (rFIX) Indication: Continuous prophylactic treatment of bleeding in…

    Published on 7/21/2014
  • CCX168: Additional Phase II data

    ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX168 Business: Inflammation Molecular target: Complement receptor 5a (CD88) Description: Small molecule complement receptor 5a (C5aR; CD88) inhibitor …

    Published on 7/21/2014
  • Cobimetinib: Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Cobimetinib (RG7421, GDC-0973) (formerly XL518) Business: …

    Published on 7/21/2014
  • Crenezumab: Phase II data

    AC Immune S.A., Lausanne, Switzerland Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Crenezumab (MABT5102A, RG7412) Business: Neurology Molecular target: Beta …

    Published on 7/21/2014
  • Crenezumab: Phase II data

    AC Immune S.A., Lausanne, Switzerland Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Crenezumab (MABT5102A, RG7412) Business: Neurology Molecular target: Beta …

    Published on 7/21/2014
  • DAG for Injection: Additional Phase I/II data

    DelMar Pharmaceuticals Inc. (OTCBB:DMPI), Vancouver, B.C. Guangxi Wuzhou Zhongheng Group Co. Ltd. (Shanghai:600252), Wuzhou, China Product: DAG for Injection (VAL-083) Business: Cancer Molecular target: DNA Description:…

    Published on 7/21/2014
  • Emend aprepitant: Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Emend aprepitant (MK-0869, MK-869) (formerly ONO-7436) Business: Gastrointestinal Molecular target: …

    Published on 7/21/2014
  • Galeterone: Additional Phase II data

    Tokai Pharmaceuticals Inc., Cambridge, Mass. Product: Galeterone (TOK-001) Business: Cancer Molecular target: Androgen receptor; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) Description: Selective androgen…

    Published on 7/21/2014
  • I-131-CLR1404: Phase Ib data

    Cellectar Biosciences Inc. (OTCQX:CLRBD), Madison, Wis. Product: I-131-CLR1404 (HOT) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) Description: Iodine-radiolabeled small molecule phosphoinositide 3…

    Published on 7/21/2014
  • JZP-110: Phase IIb data

    Aerial BioPharma LLC, Morrisville, N.C. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Product: JZP-110 (formerly ADX-N05) Business: Neurology Molecular target…

    Published on 7/21/2014
  • Lenvatinib: Additional Phase III data

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan SFJ Pharmaceuticals Inc., Pleasanton, Calif. Product: Lenvatinib (E7080) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor; Vascular …

    Published on 7/21/2014
  • Lucitanib: Additional Phase II data

    Advenchen Laboratories LLC, Moorpark, Calif. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Servier, Neuilly-sur-Seine, France Product: Lucitanib (AL3810, E-3810) Business: Cancer Molecular target: Fibroblast growth…

    Published on 7/21/2014
  • Mekinist trametinib: Additional Phase III data

    Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mekinist trametinib (GSK1120212) Business: Cancer Molecular target: MAP kinase kinase 1 (MAP2K1) (MEK1); MAP …

    Published on 7/21/2014
  • Mekinist trametinib: Phase III data

    Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mekinist trametinib (GSK1120212) Business: Cancer Molecular target: MAP kinase kinase 1 (MAP2K1) (MEK1); MAP …

    Published on 7/21/2014
  • NT-0102: Phase III data

    Neos Therapeutics Inc., Grand Prairie, Texas Product: NT-0102 Business: Neurology Molecular target: NA Description: Extended-release oral disintegrating tablet formulation of the generic methylphenidate using Rapidly …

    Published on 7/21/2014
  • Paclical micellular paclitaxel: Phase III data

    Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Product: Paclical micellular paclitaxel (OAS-PAC-100) Business: Cancer Molecular target: Tubulin Description: Water-soluble formulation of paclitaxel Indication: …

    Published on 7/21/2014
  • Rucaparib: Additional Phase I/II data

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rucaparib (CO-338) (formerly PF-01367338, AG-014699) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase-1 (…

    Published on 7/21/2014
  • SCIB1: Updated Phase I/II data

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K. Product: SCIB1 Business: Cancer Molecular target: Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT) Description: Cancer vaccine comprising the melanoma …

    Published on 7/21/2014
  • SER-109: Additional Phase I data

    Seres Health Inc., Cambridge, Mass. Product: SER-109 Business: Infectious Molecular target: NA Description: Oral mixture of microbiome organisms Indication: Treat recurrent ~Clostridium difficile infection (CDI) …

    Published on 7/21/2014
  • Tafinlar dabrafenib: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Tafinlar dabrafenib (GSK2118436) Business: Cancer Molecular target: BRAF Description: Oral BRAF protein kinase inhibitor Indication: Treat advanced or …

    Published on 7/21/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993